甲型H1N1流感pdm09和甲型H3N2疫苗在延迟流感季节有效性的中期估计，加拿大，2024/25。

IF 9.9 2区医学 Q1 INFECTIOUS DISEASES

Eurosurveillance Pub Date : 2025-01-01 DOI:10.2807/1560-7917.ES.2025.30.4.2500059

Lea Separovic, Yuping Zhan, Samantha E Kaweski, Suzana Sabaiduc, Sara Carazo, Romy Olsha, Richard G Mather, James A Dickinson, Maan Hasso, Isabelle Meunier, Agatha N Jassem, Nathan Zelyas, Ruimin Gao, Nathalie Bastien, Danuta M Skowronski

{"title":"甲型H1N1流感pdm09和甲型H3N2疫苗在延迟流感季节有效性的中期估计，加拿大，2024/25。","authors":"Lea Separovic, Yuping Zhan, Samantha E Kaweski, Suzana Sabaiduc, Sara Carazo, Romy Olsha, Richard G Mather, James A Dickinson, Maan Hasso, Isabelle Meunier, Agatha N Jassem, Nathan Zelyas, Ruimin Gao, Nathalie Bastien, Danuta M Skowronski","doi":"10.2807/1560-7917.ES.2025.30.4.2500059","DOIUrl":null,"url":null,"abstract":"The Canadian Sentinel Practitioner Surveillance Network (SPSN) reports interim 2024/25 vaccine effectiveness (VE) against acute respiratory illness due to laboratory-confirmed influenza during a delayed season of predominant A(H1N1)pdm09 and lower A(H3N2) co-circulation. Through mid-January, the risk of outpatient illness due to influenza A is reduced by about half among vaccinated vs unvaccinated individuals. Adjusted VE is 53% (95% CI: 36-65) against A(H1N1)pdm09, comprised of clades 5a.2a and 5a.2a.1, and 54% (95% CI: 29-70) against A(H3N2), virtually all clade 2a.3a.1.","PeriodicalId":12161,"journal":{"name":"Eurosurveillance","volume":"30 4","pages":""},"PeriodicalIF":9.9000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11920781/pdf/","citationCount":"0","resultStr":"{\"title\":\"Interim estimates of vaccine effectiveness against influenza A(H1N1)pdm09 and A(H3N2) during a delayed influenza season, Canada, 2024/25.\",\"authors\":\"Lea Separovic, Yuping Zhan, Samantha E Kaweski, Suzana Sabaiduc, Sara Carazo, Romy Olsha, Richard G Mather, James A Dickinson, Maan Hasso, Isabelle Meunier, Agatha N Jassem, Nathan Zelyas, Ruimin Gao, Nathalie Bastien, Danuta M Skowronski\",\"doi\":\"10.2807/1560-7917.ES.2025.30.4.2500059\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The Canadian Sentinel Practitioner Surveillance Network (SPSN) reports interim 2024/25 vaccine effectiveness (VE) against acute respiratory illness due to laboratory-confirmed influenza during a delayed season of predominant A(H1N1)pdm09 and lower A(H3N2) co-circulation. Through mid-January, the risk of outpatient illness due to influenza A is reduced by about half among vaccinated vs unvaccinated individuals. Adjusted VE is 53% (95% CI: 36-65) against A(H1N1)pdm09, comprised of clades 5a.2a and 5a.2a.1, and 54% (95% CI: 29-70) against A(H3N2), virtually all clade 2a.3a.1.\",\"PeriodicalId\":12161,\"journal\":{\"name\":\"Eurosurveillance\",\"volume\":\"30 4\",\"pages\":\"\"},\"PeriodicalIF\":9.9000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11920781/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Eurosurveillance\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2807/1560-7917.ES.2025.30.4.2500059\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eurosurveillance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2807/1560-7917.ES.2025.30.4.2500059","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

加拿大执业哨点监测网络（SPSN）报告了在甲型H1N1 pdm09和甲型H3N2共循环的延迟季节中，针对实验室确认的流感引起的急性呼吸道疾病的疫苗有效性（VE）。到1月中旬，与未接种疫苗的人相比，接种疫苗的人因甲型流感而门诊就诊的风险降低了约一半。对A(H1N1)pdm09的校正VE为53%(95% CI: 36-65)，由进化枝5a组成。2a和5a。1，和54%（95% CI: 29-70）对抗A(H3N2)，几乎所有进化枝2a.3a.1。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Interim estimates of vaccine effectiveness against influenza A(H1N1)pdm09 and A(H3N2) during a delayed influenza season, Canada, 2024/25.

The Canadian Sentinel Practitioner Surveillance Network (SPSN) reports interim 2024/25 vaccine effectiveness (VE) against acute respiratory illness due to laboratory-confirmed influenza during a delayed season of predominant A(H1N1)pdm09 and lower A(H3N2) co-circulation. Through mid-January, the risk of outpatient illness due to influenza A is reduced by about half among vaccinated vs unvaccinated individuals. Adjusted VE is 53% (95% CI: 36-65) against A(H1N1)pdm09, comprised of clades 5a.2a and 5a.2a.1, and 54% (95% CI: 29-70) against A(H3N2), virtually all clade 2a.3a.1.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Eurosurveillance INFECTIOUS DISEASES-

CiteScore

32.70

自引率

2.10%

发文量

430

审稿时长

3-8 weeks

期刊介绍： Eurosurveillance is a European peer-reviewed journal focusing on the epidemiology, surveillance, prevention, and control of communicable diseases relevant to Europe.It is a weekly online journal, with 50 issues per year published on Thursdays. The journal includes short rapid communications, in-depth research articles, surveillance reports, reviews, and perspective papers. It excels in timely publication of authoritative papers on ongoing outbreaks or other public health events. Under special circumstances when current events need to be urgently communicated to readers for rapid public health action, e-alerts can be released outside of the regular publishing schedule. Additionally, topical compilations and special issues may be provided in PDF format.